Sentences with phrase «finger nuclease»

Zinc finger nuclease mediated knockout of ADP - dependent glucokinase in cancer cell lines: effects on cell survival and mitochondrial oxidative metabolism.

An unbiased genome - wide analysis of zinc - finger nuclease specificity.

To circumvent this, a CCR5 specific zinc - finger nuclease pair (R5 - ZFNs) has been developed [23].

In that case, six patients suspended antiretroviral therapy for 12 weeks after infusion with zinc finger nuclease — altered CD4 cells.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Announced a worldwide collaboration with Sangamo Therapeutics, Inc. (Sangamo) using Sangamo's zinc finger nuclease technology platform for the development of next - generation ex vivo cell therapies in oncology.

In recent years several techniques, such as CRISPR / Cas9 or zinc finger nucleases have been experimented to directly modify the DNA of plants and animals.

«CRISPR has proven so easy and inexpensive that Dana Carroll of the University of Utah, Salt Lake City, who spearheaded the development of zinc finger nucleases, [one of its competitors,] says it has brought about the «democratization of gene targeting.

By using engineered zinc - finger nucleases (ZFNs) designed to target an integrated reporter and two endogenous rat genes, Immunoglobulin M (IgM) and Rab38, we demonstrate that a single injection of DNA or messenger RNA encoding ZFNs into the one - cell rat embryo leads to a high frequency of animals carrying 25 to 100 % disruption at the target locus.

Scientists can select from a variety of scalpels, including zinc finger nucleases, TALENs and CRISPR / Cas9.

«Before CRISPR, there was TALENS [transcription activator - like effector nucleases] and zinc finger nucleases — older technologies that were not as precise or reliable,» explains Sosa.

Talk of curing AIDS made front - page news last year, in part due to an astonishing new gene - editing technology: lab - engineered proteins called zinc finger nucleases.

And in another advance, virologist Paula Cannon of the University of Southern California used zinc finger nucleases to create human stem cells that lack CCR5.

Ultimately, this week's discourse will lead to a consensus statement providing some guidance on how to approach using this and older gene editing technologies such as zinc finger nucleases and enzymes called transcription activator - like effector nucleases, or TALENs.

Its competitors — designer proteins called zinc finger nucleases and TALENs — also precisely alter chosen DNA sequences, and several companies are already exploiting them for therapeutic purposes in clinical trials.

But CRISPR has proven so easy and inexpensive that Dana Carroll of the University of Utah, Salt Lake City, who spearheaded the development of zinc finger nucleases, says it has brought about the «democratization of gene targeting.»

They have used a different technique, called zinc finger nucleases, to disrupt a gene on T cells that HIV uses to enter the cells.

Although the study looked at CRISPR - Cas9 gene editing, the researchers believe their findings extend to other gene - editing tools such as zinc - finger nucleases (ZFN) and TAL effector nucleases.

In clinical trials already underway, for example, researchers have used an older gene - editing technique, enzymes call zinc finger nucleases, in immune cells to deactivate the gene for CCR5, a surface protein that HIV latches onto in order to infect cells.

In 2009, for example, Sangamo Therapeutics in Richmond, California, began using zinc finger nucleases to modify genes in immune cells from HIV - infected people, hoping to make the cells resistant to the virus.

In 2009, researchers at Dow AgroSciences in Indianapolis, Indiana, and Sangamo BioSciences in Richmond, California, announced that they had used enzymes called zinc - finger nucleases to insert a gene for herbicide resistance at a specific site in the maize genome (V. K. Shukla et al..

What's more, say the researchers, the cancer - causing effects of off - target deletions mistakenly created by the V (D) J enzyme need to be considered in designing site - specific enzymes for genome modification such as zinc - finger nucleases, TALENS, or CRISPRs.

In it, they sound the alarm about new genome - editing techniques known as CRISPR and zinc - finger nucleases that make it much easier for scientists to delete, add, or change specific genes.

Last year, researchers targeted and destroyed this gene in the T - cells of 12 people with HIV using custom - made proteins called zinc finger nucleases.

The trial is using a form of DNA scissors called zinc finger nucleases (ZFNs).

As an approach to inactivating CCR5, we introduced CCR5 - specific zinc - finger nucleases into human CD4 + T cells prior to adoptive transfer, but the need to protect cells from virus strains that use CXCR4 (X4) in place of or in addition to CCR5 (R5X4) remains.

Each ZFP was then fused to a modified FokI cleavage domain, active preferentially as a dimer to reduce nonspecific DNA cleavage, resulting in zinc - finger nucleases (ZFNs)[25].

Here we describe engineering a pair of zinc finger nucleases that, when introduced into human T cells, efficiently disrupt cxcr4 by cleavage and error - prone non-homologous DNA end - joining.

Previously we engineered zinc - finger nucleases (ZFNs) to specifically disrupt the CCR5 gene in primary human T cells, the predominant cell type infected and killed by HIV.

Citation: Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, Rebar EJ, et al. (2011) Engineering HIV - Resistant Human CD4 + T Cells with CXCR4 - Specific Zinc - Finger Nucleases.

These approaches, which include exotic sounding tools like zinc finger nucleases and CRISPR / Cas9, differ from more traditional ways reducing the impact of the HD mutation on cells.

A similar approach, but using a different technology (zinc finger nucleases), was reported for Huntington's disease in 2012.

Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, Ando D, Urnov FD, Galli C, Gregory PD, Holmes MC, Naldini L. Gene editing in human stem cells using zinc finger nucleases and integrase - defective lentiviral vector delivery.

Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Camisa B, Bondanza A, Casorati G, Ponzoni M, Ciceri F, Bordignon C, Greenberg PD, Holmes MC, Gregory PD, Naldini L, Bonini C. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer.

Working with proteins called zinc finger nucleases and TALENs, Zhang attempted to edit the genomes of mammalian cells with a view to engineering them.

The variety of new tools available for genetic manipulation now include lentiviral - based gene delivery, and gene editing using CRISPR / Cas9, zinc finger nucleases (ZFNs) or transcription activator - like effector nucleases (TALENs).

With the genome engineering revolution came epigenome - engineering tools - zinc finger nucleases and TALENs fused to epigenetic modifiers enabled epigenetic modifications at a user - specified locus.

Experimenting with zinc finger nucleases...

In the past, researchers have attempted to do this with gene editing tools like zinc fingers nucleases, but the process was too labor - intensive to be used on a large scale.

Zinc finger nucleases [1], [2], transcription activator - like effector nucleases [3], [4] and homing meganucleases [5] have provided powerful tools to induce targeted mutations in the form of small insertions or deletions derived from DNA break repair of nonhomologous end joining (NHEJ) or homologous recombination.

Dow Agrosciences wanted to see if engineered zinc finger nucleases could speed up genetic engineering.

Eventually, the team of Dow and Sangamo scientists showed that it could engineer zinc finger nucleases that gave a two - for - one deal.

Ultimately this will include the expanding repertoire of advanced technologies such as clustered regularly interspaced short palindromic repeats (CRISPR), CRISPR - associated protein 9 (Cas9), and zinc - finger nucleases (ZFNs)(46) along with the new clinical indications and markets that they address.

Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.

Addgene depositor Charles Gersbach used paired zinc finger nucleases to remove exon 51 in DMD patient myoblasts.

Two newer gene - editing methods — zinc finger nucleases, used since the late 1990s, and TALENs, first described in 2011 — allowed more precise modifications, he says, «but there was a real art and skill required, and only a handful of labs could do those.»

Not exact matches

Meanwhile, Cellectis announced it now has «an umbrella patent» that its CEO, Andre Choulika, says «covers most of the gene editing procedures done with a nuclease,» including those based on CRISPR - Cas 9, TALENs, zinc fingers, and many meganucleases.